Red/Purple callout.
-
-
There is a mixing of clinical and non-clinical claims in close proximity. Please separate the content with clear and separate visual distinction.
-
MOA information is incomplete and is cherry picking the full context of the Mechanism of Action section. Please complete this section.
-
Selection of the pneumonitis claim on it's own, does not reflect an attitude of caution for safety information. Please remove or complete the presentation of the safety information.
-
-
Revise as noted by removing pneumonitis claim.
Add MOA after MOA claim: "ARRADICAN reactivates tumour specific cytotoxic T lymphocytes in the tumour microenvironment by inhibiting the PD-1 receptor from binding to its ligands and thereby also reactivates anti-tumour immunity."